Elsevier

Immunology Letters

Volume 216, December 2019, Pages 63-69
Immunology Letters

CD3-CD56+ NK cells display an inflammatory profile in RR-MS patients

https://doi.org/10.1016/j.imlet.2019.10.006Get rights and content

Highlights

  • CD3CD56+ NK cells and their NKG2D expression are elevated under IFN-β treatment.

  • IL-22 levels of CD3CD56+ NK cells are increased as a consequence of IFN-β therapy.

  • IFN-β treatment directs NK cells toward a pro-inflammatory status.

Abstract

Multiple Sclerosis (MS) is an immune-mediated and neurodegenerative disease of central nervous system. Relapsing-remitting (RR)-MS occurring with acute attacks and remissions, is the most common clinical type of MS. There are different strategies applied in first-line treatment of RR-MS patients such as interferon-beta (IFN-β) and glatiramer acetate. In this study, activating and inhibitory receptor expressions and interleukin (IL)-22 levels of NK cells were investigated in RR-MS patients with or without IFN-β therapy. Activating receptor expression and IL-22 levels of NK cells were increased in RR-MS patients under IFN-β therapy. Elevated NK cells with activating profile and increased IL-22 under IFN-β therapy suggest that IFN-β treatment might direct NK cells toward a pro-inflammatory status.

Introduction

Multiple Sclerosis (MS) is an immune-facilitated, chronic, neurodegenerative and demyelinating inflammatory central nervous system (CNS) disorder. The subgroups of MS are defined by the clinical course [1]. Relapsing-remitting (RR)-MS constitutes about 85–90% of MS patients and it occurs with acute attacks (relapses) and remissions [2]. The majority of MS patients initially present a single attack known as clinically isolated syndrome (CIS) [3]. Although the pathogenesis of MS is not well defined, autoreactive CD4+ T cells are thought to be responsible for attacking myelin antigens that cause tissue damage and inflammatory responses resulting in demyelination and neuronal damage [4,5]. Also, several studies revealed the contribution of the cells of innate immunity including Natural Killer (NK) cells in MS pathogenesis [6]. Because of the regulatory and cytotoxic functions of NK cells, their roles in MS pathogenesis has gained importance in recent years.

NK cells comprising 5–15% of leukocytes in healthy individuals are characterized phenotypically by the expression of CD56 but not CD3 molecule on their surface membrane. CD56 expression of NK cells is increased upon activation [[7], [8], [9]] suggesting CD56 as an activation marker [10] whereas immunosuppressive agents reduce their frequencies [11].

NK cells are well known by their cytolytic capabilities in early defense against tumor cells as well as pathogens, while having immunoregulatory properties through cytokine secretion revealing their importance in innate immunity [12]. Cellular functions of NK cells are governed by the balance between signals of activating and inhibitory receptors present on NK cells [13,14]. Activating receptors include NKG2D (Natural killer group 2, member D), 2B4 and the natural cytotoxicity receptors (NCRs) such as NKp30, NKp44 and NKp46. These receptors bind ligands induced by infection, tumors or cellular stress [15] and deliver activating signals to NK cells for cytotoxicity or cytokine secretion. NK cell activation is mainly regulated by the inhibitory receptors specific for MHC class I molecules [16]. Killer-cell immunoglobulin-like receptors (KIRs) and CD94-NKG2A heterodimer are the main groups of inhibitory MHC class I–specific receptors [17].

NK cells might be classified by their cytokine secretion profiles such as NK1, NK2 or NK22 cells. NK22 cells produce interleukin-22 (IL-22) upon stimulation with IL-12, IL-18 and IL-23 [18,19] whereas IL-27 suppresses the secretion of IL-22 from CD4+ T cells [20]. IL-22 is a pro-inflammatory cytokine with a protective role in the regeneration of epithelial tissues and host defence in mucosal barriers such as intestine, oral mucosa or lung [21]. There are also many studies demonstrating the possible contribution of IL-22 in neurological diseases [22]. However, contradictory findings were obtained from the studies investigating the involvement of IL-22 in autoimmune diseases [[23], [24], [25]]. IL-22RA2 was defined as a risk gene [26] and an inflammatory role was attributed to IL-22 in MS [27,28]. Recently, we have demonstrated a tendency to increase in IL-22 levels of NK cell subsets in RR-MS patients in response to cytokine stimulations [29]. However, the possible contribution of IL-22 in MS pathogenesis still needs to be elucidated.

In this study, to investigate the activation status of CD3CD56+ NK cells in treated and untreated RR-MS in comparison with CIS patients, expression of NKG2A, NKG2D and NKp44 were analysed. In addition, plasma IL-22 levels as well as IL-22 content of CD3CD56+ NK cells in response to IL-2, IL-10, IL-12 and IL-27 were measured for exploring the possible contribution of IL-22 in RR-MS pathogenesis.

Section snippets

Subjects

Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Neurology followed up the patients and directed them for enrollment to this study. This study was approved by Local Ethical Committee of Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, in compliance with Helsinki declaration and written informed consents were taken from all patients subsequent to their enrollment. The study group consisted of untreated (n = 9) and interferon-beta (IFN-β) treated (at

Ex vivo frequencies of NK cells and activating/inhibitory receptors

Peripheral blood samples obtained from patients were freshly stained for CD3 and CD56 molecules for detecting CD3CD56+ NK cells (Fig. 1A) prior to measurement of their activating and inhibitory receptor expressions. Ex vivo CD3CD56+ NK cell frequencies of treated RR-MS patients were significantly increased in comparison with untreated RR-MS patients (p = 0.019) although the percentage of CD3+ T cells were similar (Fig.1B).

In addition, the percentage of NKG2D+CD3CD56+ NK cells of untreated

Discussion

As we have recently confirmed [29], IFN-β treatment was demonstrated to increase CD3CD56bright NK cell subset frequencies of RR-MS patients in various studies [31]. In this study, total CD3CD56+ NK cells of RR-MS patients were also shown to be increased following IFN-β treatment though CD3+ T cell frequencies did not vary between patient groups. This finding might indicate that IFN-β treatment directly affect NK cell ratio, regardless of whether CD3+ T cell frequencies decrease. To explore

Declaration of Competing Interest

All authors declare that they have no financial or non-financial competing interests.

Acknowledgments

We thank Erdem Tuzun, MD for critical reading of the manuscript. This study was funded by Scientific Research Projects Coordination Unit (BAP) of Istanbul University, Turkey (Project number: 18423) and The Scientific and Technological Research Council of Turkey (TUBITAK, Project number: 112S005).

References (65)

  • J.E. Martinez-Rodriguez et al.

    Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis

    Clin. Immunol.

    (2011)
  • M. Allez et al.

    CD4+NKG2D+ T cells in Crohn’s disease mediate inflammatory and cytotoxic responses through MICA interactions

    Gastroenterology

    (2007)
  • J.L. Fernandez-Morera et al.

    Soluble MHC class I chain-related protein B serum levels correlate with disease activity in relapsing-remitting multiple sclerosis

    Hum. Immunol.

    (2008)
  • C. Cerboni et al.

    Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis

    Blood

    (2007)
  • B. Zitti et al.

    Natural killer cells in inflammation and autoimmunity

    Cytokine Growth Factor Rev.

    (2018)
  • H. Schlums et al.

    Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function

    Immunity

    (2015)
  • M. Paroni et al.

    Recognition of viral and self-antigens by TH1 and TH1/TH17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses

    J. Allergy Clin. Immunol.

    (2017)
  • L. Lu et al.

    Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway

    Immunity

    (2007)
  • A. Laroni et al.

    Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis

    J. Autoimmun.

    (2016)
  • H.F. Pan et al.

    Emerging role of interleukin-22 in autoimmune diseases

    Cytokine Growth Factor Rev.

    (2013)
  • K. Wolk et al.

    IL-22 increases the innate immunity of tissues

    Immunity

    (2004)
  • E. Witte et al.

    Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection

    Cytokine Growth Factor Rev.

    (2010)
  • F.D. Lublin et al.

    Defining the clinical course of multiple sclerosis: the 2013 revisions

    Neurology

    (2014)
  • R. Weissert

    The immune pathogenesis of multiple sclerosis

    J. Neuroimmune Pharmacol.

    (2013)
  • A.P. Jones et al.

    Circulating immune cells in multiple sclerosis

    Clin. Exp. Immunol.

    (2017)
  • H.L. Weiner

    A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis

    J. Neurol.

    (2008)
  • Y. Liu et al.

    Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy

    Clin. Cancer Res.

    (2013)
  • S. Anguille et al.

    Interleukin-15 dendritic cells harness NK cell cytotoxic effector function in a contact- and IL-15-Dependent manner

    PLoS One

    (2015)
  • H.H. Van Acker et al.

    CD56 in the Immune System: More Than a Marker for Cytotoxicity?

    Front. Immunol.

    (2017)
  • L.L. Lanier

    Up on the tightrope: natural killer cell activation and inhibition

    Nat. Immunol.

    (2008)
  • E.O. Long et al.

    Controlling natural killer cell responses: integration of signals for activation and inhibition

    Annu. Rev. Immunol.

    (2013)
  • E.O. Long

    Negative signaling by inhibitory receptors: the NK cell paradigm

    Immunol. Rev.

    (2008)
  • Cited by (11)

    View all citing articles on Scopus
    View full text